These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 31355308)

  • 21. Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome.
    Chen JJ; Flanagan EP; Jitprapaikulsan J; López-Chiriboga ASS; Fryer JP; Leavitt JA; Weinshenker BG; McKeon A; Tillema JM; Lennon VA; Tobin WO; Keegan BM; Lucchinetti CF; Kantarci OH; McClelland CM; Lee MS; Bennett JL; Pelak VS; Chen Y; VanStavern G; Adesina OO; Eggenberger ER; Acierno MD; Wingerchuk DM; Brazis PW; Sagen J; Pittock SJ
    Am J Ophthalmol; 2018 Nov; 195():8-15. PubMed ID: 30055153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis.
    Ramanathan S; Prelog K; Barnes EH; Tantsis EM; Reddel SW; Henderson AP; Vucic S; Gorman MP; Benson LA; Alper G; Riney CJ; Barnett M; Parratt JD; Hardy TA; Leventer RJ; Merheb V; Nosadini M; Fung VS; Brilot F; Dale RC
    Mult Scler; 2016 Apr; 22(4):470-82. PubMed ID: 26163068
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis.
    Jitprapaikulsan J; Chen JJ; Flanagan EP; Tobin WO; Fryer JP; Weinshenker BG; McKeon A; Lennon VA; Leavitt JA; Tillema JM; Lucchinetti C; Keegan BM; Kantarci O; Khanna C; Jenkins SM; Spears GM; Sagan J; Pittock SJ
    Ophthalmology; 2018 Oct; 125(10):1628-1637. PubMed ID: 29716788
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of clinical characteristics and prognoses in patients with different AQP4-Ab and MOG-Ab serostatus with neuromyelitis optica spectrum disorders.
    Du Q; Shi Z; Chen H; Zhang Y; Wang J; Qiu Y; Zhao Z; Zhang Q; Zhou H
    J Neuroimmunol; 2021 Apr; 353():577494. PubMed ID: 33515897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration.
    Havla J; Kümpfel T; Schinner R; Spadaro M; Schuh E; Meinl E; Hohlfeld R; Outteryck O
    J Neurol; 2017 Jan; 264(1):139-151. PubMed ID: 27844165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands.
    van Pelt ED; Wong YY; Ketelslegers IA; Hamann D; Hintzen RQ
    Eur J Neurol; 2016 Mar; 23(3):580-7. PubMed ID: 26593750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis.
    Chen JJ; Bhatti MT
    Curr Opin Neurol; 2020 Feb; 33(1):47-54. PubMed ID: 31743235
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
    Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
    Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Optic neuropathy in positive anti-MOG antibody syndrome].
    Merabtene L; Vignal Clermont C; Deschamps R
    J Fr Ophtalmol; 2019 Dec; 42(10):1100-1110. PubMed ID: 31732265
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The prevalence and prognostic value of myelin oligodendrocyte glycoprotein antibody in adult optic neuritis.
    Liu H; Zhou H; Wang J; Sun M; Teng D; Song H; Xu Q; Wei S
    J Neurol Sci; 2019 Jan; 396():225-231. PubMed ID: 30522039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical presentation of optic neuritis with autoantibodies anti-myelin oligodendrocyte glycoprotein.
    Ducloyer JB; Michel L; Wiertlewski S; Lebranchu P
    Eur J Ophthalmol; 2019 Mar; 29(2):257-261. PubMed ID: 29972029
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effects of intravenous methylprednisolone pulse therapy on recurrent optic neuritis associated with aquaporin 4 antibody seropositive neuromyelitis optica].
    Guo ST; Li Z; Jiang LB; Wu RH; Peng JT; Wang JW; Wei WB
    Zhonghua Yan Ke Za Zhi; 2020 Jul; 56(7):509-513. PubMed ID: 32842332
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
    Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
    J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: Blood-brain barrier breakdown and peripheral plasmablasts.
    Tanaka S; Hashimoto B; Izaki S; Oji S; Fukaura H; Nomura K
    Mult Scler Relat Disord; 2020 Jun; 41():102005. PubMed ID: 32114369
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High association of MOG-IgG antibodies in children with bilateral optic neuritis.
    Wendel EM; Baumann M; Barisic N; Blaschek A; Coelho de Oliveira Koch E; Della Marina A; Diepold K; Hackenberg A; Hahn A; von Kalle T; Karenfort M; Kornek B; Lechner C; Leiz S; Merkenschlager A; Nosadini M; Sartori S; Schanda K; Schimmel M; Seemann L; Tüngler V; Waltz S; Wegener-Panzer A; Wiegand G; Reindl M; Rostásy K
    Eur J Paediatr Neurol; 2020 Jul; 27():86-93. PubMed ID: 32327391
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Characteristics of Pediatric Optic Neuritis With Myelin Oligodendrocyte Glycoprotein Seropositive: A Cohort Study.
    Chen Q; Zhao G; Huang Y; Li Z; Sun X; Lu P; San Y; Wang M; Tian G
    Pediatr Neurol; 2018 Jun; 83():42-49. PubMed ID: 29778487
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epidemiologic and Clinical Characteristics of Optic Neuritis in Japan.
    Ishikawa H; Kezuka T; Shikishima K; Yamagami A; Hiraoka M; Chuman H; Nakamura M; Hoshi K; Goseki T; Mashimo K; Mimura O; Yoshitomi T; Tanaka K;
    Ophthalmology; 2019 Oct; 126(10):1385-1398. PubMed ID: 31196727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unfavorable Structural and Functional Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis.
    Jelcic I; Hanson JVM; Lukas S; Weber KP; Landau K; Pless M; Reindl M; Weller M; Martin R; Lutterotti A; Schippling S
    J Neuroophthalmol; 2019 Mar; 39(1):3-7. PubMed ID: 30015656
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simultaneous bilateral optic neuritis in China: clinical, serological and prognostic characteristics.
    Kang H; Liu Z; Li H; Chen T; Ai N; Xu Q; Cao S; Tao Y; Wei S
    Acta Ophthalmol; 2019 May; 97(3):e426-e434. PubMed ID: 30632682
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Five-year visual outcomes after optic neuritis in anti-MOG antibody-associated disease.
    Akaishi T; Himori N; Takeshita T; Misu T; Takahashi T; Takai Y; Nishiyama S; Fujimori J; Ishii T; Aoki M; Fujihara K; Nakazawa T; Nakashima I
    Mult Scler Relat Disord; 2021 Nov; 56():103222. PubMed ID: 34461572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.